CDT1 Antibody (JA30-81)

Western Blot: CDT1 Antibody (JA30-81) [NBP2-66768] - Analysis of CDT1 on Hela cell using anti-CDT1 antibody at 1/1,000 dilution.

Immunohistochemistry-Paraffin: CDT1 Antibody (JA30-81) [NBP2-66768] - Analysis of paraffin-embedded human skin tissue using anti-CDT1 antibody. Counter stained with hematoxylin.

Product Discontinued

CDT1 Antibody (JA30-81) Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Recombinant protein within Human CDT1 aa 497-546 / 546. (SwissProt: Q9H211 Human)
• Localization: Nucleus.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: CDT1
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 1:25-1:50
  • Immunoprecipitation
  • Western Blot 1:500-1:1000

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: TBS (pH7.4), 0.05% BSA, 40% Glycerol
• Preservative: 0.05% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for CDT1 Antibody (JA30-81)

• chromatin licensing and DNA replication factor 1
• DNA replication factor Cdt1
• Double parked homolog
• Double parked, Drosophila, homolog of
• DUPRIS2

Background

Geminin is a protein that inhibits DNA replication by preventing the loading of MCM complex on chromatin. Human CDT1 is a 65kDa protein that contains 546 amino acids and coimmunoprecipitates with Geminin. Inhibition of DNA replication by Geminin in cell-free cDNA replication extracts can be reversed by the addition of excess CDT1. In the normal cell cycle, CDT1 is present only in G1 and S phases, whereas Geminin is present in S and G2 phases. Wohlschlegel et al. (2000) concluded that their results suggest that Geminin inhibits inappropriate origin firing by targeting CDT1. This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animals cells produce the protein, which stimulates the animals immune system to produce antibodies against that particular protein. A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein. Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CDT1